Tags

Type your tag names separated by a space and hit enter

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.
Clin Infect Dis. 2020 Mar 28 [Online ahead of print]CI

Abstract

BACKGROUND

The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.

METHODS

A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed.

RESULTS

Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006).

CONCLUSIONS

The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.

Authors+Show Affiliations

Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.Department of Critical Care Medicine,Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China. The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.School of Public Health, Xiamen University, Xiamen, Fujian, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China. The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen, Fujian, China. School of Public Health, Xiamen University, Xiamen, Fujian, China.Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China. The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32221519

Citation

Zhao, Juanjuan, et al. "Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2020.
Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020.
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Qian, S., Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., ... Zhang, Z. (2020). Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciaa344
Zhao J, et al. Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. Clin Infect Dis. 2020 Mar 28; PubMed PMID: 32221519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. AU - Zhao,Juanjuan, AU - Yuan,Quan, AU - Wang,Haiyan, AU - Liu,Wei, AU - Liao,Xuejiao, AU - Su,Yingying, AU - Wang,Xin, AU - Yuan,Jing, AU - Li,Tingdong, AU - Li,Jinxiu, AU - Qian,Shen, AU - Hong,Congming, AU - Wang,Fuxiang, AU - Liu,Yingxia, AU - Wang,Zhaoqin, AU - He,Qing, AU - Li,Zhiyong, AU - He,Bin, AU - Zhang,Tianying, AU - Fu,Yang, AU - Ge,Shengxiang, AU - Liu,Lei, AU - Zhang,Jun, AU - Xia,Ningshao, AU - Zhang,Zheng, Y1 - 2020/03/28/ PY - 2020/03/12/received PY - 2020/3/30/entrez PY - 2020/3/30/pubmed PY - 2020/3/30/medline KW - COVID-19 KW - SARS-CoV-2 KW - antibody JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin. Infect. Dis. N2 - BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/32221519/full_citation L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciaa344 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.